Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 5/20 | 0.34 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801298 | 0.97 | L3MBTL1 (0.47) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL18159675 | 0.97 | L3MBTL1 (0.47) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL16801213 | 0.95 | L3MBTL1 (0.50) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL17485017 | 0.94 | L3MBTL1 (0.46) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL16799960 | 0.93 | L3MBTL1 (0.45) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL16801214 | 0.92 | L3MBTL1 (0.47) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL21226922 | 0.92 | L3MBTL1 (0.42) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL17485019 | 0.90 | L3MBTL1 (0.43) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL17485018 | 0.90 | L3MBTL1 (0.43) | L3MBTL1KDM4EATMEDNRAEDNRB | |
| SCHEMBL16801444 | 0.88 | L3MBTL1 (0.43) | L3MBTL1KDM4EATMEDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-10374170-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2019-08-06 | — | — | US | disclosed |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885 |
| US-10374170-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885 |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885 |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | L3MBTL1 1480/4885KDM4E 710/4885ATM 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.